Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Extrinsic and Intrinsic Pathways of Hemostasis

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Efficacy and Safety of Rapid Dose Escalation of Methotrexate in Rheumatoid Arthritis (Results of the Multicenter METEOR Study).

Doklady. Biochemistry and biophysics·2026

Same author

[Predictors of ineffective therapy in patients with rheumatoid arthritis requiring bDMARDs/JAKi switching: data from a single-center prospective study].

Terapevticheskii arkhiv·2026

Same author

[Relationship between vitamin D and osteoarthritis].

Terapevticheskii arkhiv·2025

Same author

The Efficacy and Safety of BCD-180, an Anti-TRBV9+ T cell Monoclonal Antibody, in Patients with Active Radiographic Axial Spondyloarthritis: 36-week Results from the Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study ELEFTA.

Doklady. Biochemistry and biophysics·2025

Same author

[Experience with the use of undenatured type II collagen in patients with stage III knee osteoarthritis: a multicenter, prospective, double-blind, placebo-controlled, randomized trial].

Terapevticheskii arkhiv·2025

Same author

[Russian Cross-disciplinary Consensus on the diagnosis and treatment of spondyloarthritis associated with inflammatory bowel diseases].

Terapevticheskii arkhiv·2025

Search research articles

Related Experiment Video

Updated: May 13, 2025

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Thrombotic Antiphospholipid Syndrome: Recurrent Thromboses.

T M Reshetnyak^1,2, F A Cheldieva³, S I Glukhova³

¹Nasonova Research Institute of Rheumatology, Moscow, Russia. t_reshetnyak@yahoo.com.

Doklady. Biochemistry and Biophysics

|May 12, 2025

Summary

Recurrent thrombosis in antiphospholipid syndrome (APS) is common, particularly with triple IgG antiphospholipid antibody (aPL) positivity and obesity. Specific IgG aPLs like IgG aCL, IgG aß2GP1, IgG aß2GP1-D1, and IgG aPS/PT are key risk factors.

Keywords:

antibodies to cardiolipin antibodies to phosphatidylserine/prothrombin complex antibodies to ß2glycoprotein 1 antiphospholipid antibodies antiphospholipid syndrome recurrent thromboses systemic lupus erythematosus

More Related Videos

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

Related Experiment Videos

Last Updated: May 13, 2025

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

Area of Science:

Immunology
Hematology
Rheumatology

Background:

Antiphospholipid syndrome (APS) is characterized by thromboembolic events in the presence of antiphospholipid antibodies (aPL).
Understanding recurrent thrombosis and its risk factors in APS is crucial for patient management.

Purpose of the Study:

To evaluate the incidence of recurrent thrombosis in APS patients.
To identify risk factors associated with recurrent thrombosis in APS.

Main Methods:

Retrospective study of 98 APS patients (2014-2023).
Assessed antiphospholipid antibodies (aPL) including IgG/IgM aCL, IgG/IgM aß2GP1, IgG aß2GP1-D1, IgG/IgM aPS/PT using ELISA and CLA.
Determined thrombotic risk factors, including obesity.

Main Results:

Thrombosis recurrence occurred in 63% of patients.
Direct oral anticoagulants (DOACs) were associated with the highest recurrence rate.
Triple IgG aPL positivity (IgG aCL, IgG aß2GP1, IgG aß2GP1-D1) and IgG aPS/PT positivity were significant risk factors.
Obesity increased the risk of recurrent thrombosis fivefold.

Conclusions:

Recurrent thrombosis in APS is strongly linked to specific IgG aPLs (IgG aCL, IgG aß2GP1, IgG aß2GP1-D1, IgG aPS/PT).
Triple IgG aPL positivity in any combination significantly elevates recurrent thrombosis risk.
Obesity is a significant independent risk factor for recurrent thrombosis in APS.